| For: | Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol 2026; 18(2): 114960 [PMID: 41694036 DOI: 10.4330/wjc.v18.i2.114960] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v18/i2/114960.htm |
| Number | Citing Articles |
| 1 |
Muhammad Reva Aditya, Frengki Prabowo Saputro Wijayanto, Artha Maressa Theodora Simanjuntak, Michael Owen Hogipranata, Rizki Hari Mulia, Budi Satrijo, Hikmawan Wahyu Sulistomo. Comparative Effects of Probiotics, Prebiotics, and Synbiotics on Clinical Outcomes in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Probiotics and Antimicrobial Proteins 2026; doi: 10.1007/s12602-026-11158-9
|
| 2 |
Carine El Hayek, Fredy Kahkedjian, Ghadir Amin, George W. Booz, Fouad A. Zouein. Microbial mechanisms in atherosclerosis: Revisiting the infectious hypothesis. Atherosclerosis Plus 2026; 65 doi: 10.1016/j.athplu.2026.100602
|
| 3 |
Lucio Giuseppe Granata, Simona Giubilato, Francesca Campanella, Francesco Amico, Stefania Angela Di Fusco, Furio Colivicchi. Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1886347
|
| 4 |
Madia Lozupone. Advancements in longevity pharmacology research – are we finally seeing clinical progression?. Expert Opinion on Investigational Drugs 2026; 35(7) doi: 10.1080/13543784.2026.2698526
|
| 5 |
António Mesquita-Lousada, Antónia Rocha-Melo-Sousa, Carolina Teixeira, Tiago Rodrigues Guimarães, Mário Marques-Vieira, José Paulo Andrade, Hugo Ribeiro, Manuel Neiva-Sousa, João Rocha-Neves. Novel Therapies, Residual Risk, Familial Hypercholesterolemia, and Digital Tools: Multispecialty Insights from a Dyslipidemia Management Survey. Journal of Clinical Medicine 2026; 15(11) doi: 10.3390/jcm15114205
|
| 6 |
Sajid Ali, Muhammad Siraj. Low-dose colchicine for atherosclerotic cardiovascular disease and the return of inflammation-targeted pharmacotherapy. Expert Opinion on Pharmacotherapy 2026; 27(11) doi: 10.1080/14656566.2026.2705345
|
| 7 |
Xiaohui Dou, Xijuan Zhang, Liang Zeng, Xiaoyan Hu, Liheng Zeng, Yahui Wan, Xuhong Jiang, Mingxia Ge, Xiaoyan Huang. Development of a Prognostic Model for MACE in Atherosclerosis Based on MTHFR and Serum Markers. Clinical and Applied Thrombosis/Hemostasis 2026; 32 doi: 10.1177/10760296261476828
|
| 8 |
Wanqian Yu, Yuanbin Zhao, Wansong Hu, Qinghua Wu, Ping Li, Zhiwen Luo. A Multidimensional Predictive Model Integrating Serum Immunometabolic Markers and Imaging Parameters for Atherosclerosis Prognosis: A Single‐Center Cohort Study. International Journal of Clinical Practice 2026; 2026(1) doi: 10.1155/ijcp/9306994
|